HomeProductsBioactive CompoundsTransporters & Ion ChannelsP-GpValspodar
Chemical structure of CAS 121584-18-7

Valspodar

In Stock•Starting at $250 for 1 mg•Purity ≥ 98%
CAS No.121584-18-7
MDL No.MFCD00907207
MFC63H111N11O12
MW1214.60
InChI KeyYJDYDFNKCBANTM-QCWCSKBGSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98%$250In Stock
5 mgTo Be Confirmed$634In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

SDZ PSC 833 is a homodetic cyclic peptide.

CAS No.121584-18-7
Product NameValspodar

Biological Targets

ABCB1

Associated Conditions

acute erythroleukemia·acute myelomonocytic leukemia·acute myeloblastic leukemia without maturation·plasma cell neoplasm·acute megakaryoblastic leukaemia·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.

British journal of pharmacology • Vol. 135, Issue 7 • 2002
PMID: 11934808PMC: PMC1573286DOI: 10.1038/sj.bjp.0704620

Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione S-transferase.

Toxicology and applied pharmacology • Vol. 183, Issue 2 • 2002
PMID: 12387749

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 7, Issue 5 • 2001
PMID: 11350887

Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic.

Molecular pharmacology • Vol. 60, Issue 2 • 2001
PMID: 11455017DOI: 10.1124/mol.60.2.302

Documentation

Similar Products